Clinical Trial Update: Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating panobinostat and everolimus in metastatic or unresectable renal cell cancer after failure of sunitinib or sorafenib; study status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• Panobinostat (Panobinostat)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-05-17